Company Update Safe Harbor

Company Update Safe Harbor

August 2016 Company Update Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report. © MorphoSys AG, Company Update - August 2016 2 MorphoSys at a Glance MorphoSys is developing a pipeline of truly differentiated therapeutic antibodies built using proprietary technologies Munich, Germany-based biopharmaceutical company The industry’s largest antibody therapeutic pipeline assembled using proprietary technologies: − 104 active therapeutic programs − 27 antibodies in clinical trials Growing portfolio of attractive proprietary assets Strong balance sheet with recurring cash-flows supports growing investment in R&D Successful track-record of partnering world-wide Listed on the German TecDAX © MorphoSys AG, Company Update - August 2016 3 Powerful Technology Base Ensures Pipeline Sustainability Innovative Targets GPCRs, ion channels Immune checkpoints MHC-presented, tumor- associated peptides Source of novel targets Proprietary Platforms Human antibody library Protein optimization DIFFERENTIATED DRUG CANDIDATES Lanthipeptides © MorphoSys AG, Company Update - August 2016 4 The MorphoSys Pipeline 27 Clinical Product Candidates, 104 Total Most advanced development stage Program Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3 Guselkumab (CNTO1959) Janssen (J&J) IL23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease MOR208 - CD19 ALL, CLL, NHL MOR202 - CD38 Multiple myeloma MOR103/GSK3196165 GSK GM-CSF Inflammation Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors BI–836845 BI IGF-1 Solid tumors Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases BHQ880 Novartis DKK-1 Multiple myeloma BPS804 Mereo/Novartis Sclerostin Brittle bone syndrome CNTO3157 Janssen (J&J) - Inflammation CNTO6785 Janssen (J&J) - Inflammation Elgemtumab (LJM716) Novartis HER3 Cancer Tarextumab (OMP-59R5) Oncomed Notch 2 Solid tumors Tesidolumab (LFG316) Novartis C5 Eye diseases VAY736 Novartis BAFF-R Inflammation Utomilumab (PF-05082566) Pfizer 4-1BB Solid tumors MOR209/ES414 Aptevo PSMA/CD3 Prostate cancer MOR106 Galapagos - Inflammation BAY1093884 Bayer TFPI Hemophilia NOV-7 Novartis - Eye diseases NOV-8 Novartis - Inflammation NOV-9 Novartis - Diabetic eye diseases NOV-10 Novartis - Cancer NOV-11 Novartis - Blood disorders NOV-12 Novartis - Prevention of thrombosis Vantictumab (OMP-18R5) Oncomed Fzd 7 Solid tumors MOR107 (LP2) - AT2-R Fibrosis Immuno-oncology program Merck - Cancer Immuno-oncology program Immatics - Cancer 90 Partnered Discovery Programs 6 MOR programs - - Various 13 MOR Programs 1 Outlicensed Program In addition, 23 partnered programs in preclinic, and 45 partnered programs in discovery © MorphoSys AG, Company Update - August 2016 5 The MOR Portfolio 5 Clinical Product Candidates, 14 Total Program Indication Target Discovery Preclinic Phase 1 Phase 2 Phase 3 Unpartnered MOR208 DLBCL FTD, orphan status US & EU CD19 CLL Orphan status US & EU MOR202 Multiple myeloma CD38 MOR107 Fibrosis AT2-R Immuno-oncology MHC-associated program Cancer peptides 6 Programs Various Various Co-development & co-promotion MOR209/ES414 (Emergent) Prostate cancer PSMA / CD3 MOR106 (Galapagos) Inflammation Undisclosed Immuno-oncology program Cancer Undisclosed (Merck Serono) Outlicensed to GSK RA MOR103/ GM-CSF GSK3196165 Osteoarthritis of the hand © MorphoSys AG, Company Update - August 2016 6 MOR208 First- & Best-in Class Potential CD19 is an ideal target in NHL because CD19 is broadly and homogeneously expressed − Across different NHL subtypes incl. DLBCL and CLL CD19 conveys a survival signal for B cells − Signaling via PI3K/AKT and c-Myc − Especially important for an extended treatment CD19 expression seems to be preserved − Even after pretreatments targeting B cells MOR208 is an Fc-enhanced, humanized IgG1 antibody targeting CD19 Fc modification leads to dramatically enhanced B cell depletion by ADCC, ADCP and direct cytotoxicity Straightforward manufacturing ADCC Strong pre-clinical support for combo therapy ADCC, antibody dependent cellular cytotoxicity; ADCP, antibody dependent cell phagocytosis © MorphoSys AG, Company Update - August 2016 7 MOR208 in R/R NHL Strong Single Agent Efficacy Response Rate DLBCL iNHL incl. FL in evaluable patients* n=35 n=45 n(%) Disease Control Rate (DCR) 14 (40%) 33 (73%) Overall Response (ORR) 9 (36%) 13 (33%) Complete response (CR) 2 (6%) 5 (11%) Partial response (PR) 7 (20%) 8 (18%) Stable disease (SD) 5 (14%) 20 (44%) DCR was considered to be a relevant efficacy endpoint as the majority of patients with stable disease had marked target lesion shrinkage but as per study design were not treated beyond cycle 3 *Investigator assessed Jurczak et al., Abstract #7545, ASCO 2016 © MorphoSys AG, Company Update - August 2016 8 MOR208 Comprehensive Clinical Development Plan Indication 2016 2017 2018 NHL MOR208 (12 mg/kg); N=92 DLBCL L-MIND: MOR208 (12mg/kg) + lenalidomide; 2nd line R/R; N~80 B-MIND: Safety evaluation leading into anticipated pivotal study MOR208 (12 mg/kg) + bendamustine vs. rituximab + bendamustine; 2nd line R/R; N~330 CLL COSMOS: MOR208 (12mg/kg) + combo partner; BTKi-failures MOR208 (9mg/kg) + lenalidomide; R/R, naive & Richter’s Transformation N~80 (Ohio State Univ. IIT) MOR208 + ibrutinib in ibrutinib failures } Phase 2 Phase 2/3 IIT: Investigator-initiated trial © MorphoSys AG, Company Update - August 2016 9 MOR202 A Novel Antibody for Multiple Myeloma Fully human monoclonal HuCAL IgG1 antibody Targeting a unique epitope of CD38 Inducing potent immune effector mechanisms ADCC and ADCP Status/Clinical Data: Clinical data from ongoing phase 1/2a study in multiple myeloma were presented at ASCO 2016 MOR202 (8 mg/kg) plus Pom/Dex in r/r multiple myeloma (MM) patients shows two complete responses (CR) out of four patients treated per protocol MOR202 (8 mg/kg) plus Len/Dex in MM shows two partial responses (PR) and one very good partial response (VGPR) out of the four patients MOR202 administered in doses of up to 16 mg/kg as a 2-hour intravenous infusion with ADCC = Antibody-Dependent Cell-Mediated Cytotoxicity; low incidence of infusion-related reactions ADCP = Antibody-Dependent Cell-Mediated Phagocytosis; (IRR) CDC = Complement-Dependent cytotoxicity © MorphoSys AG, Company Update - August 2016 10 Clinical Programs from Partnered Discovery Alliances (I) Program Partner Target Indication Phase 1 Phase 2 Phase 3 Guselkumab Janssen/J&J IL23p19 Psoriasis (VOYAGE 1) (CNTO1959) Psoriasis (VOYAGE 2) Psoriasis (NAVIGATE) Pustular/Erythrodermic psoriasis Moderate to severe plaque-type psoriasis Palmoplantar pustulosis Active psoriatic arthritis Gantenerumab Roche Amyloid-ß Mild Alzheimer‘s disease Prodromal Alzheimer‘s disease Genetically predisposed Safety, Tolerability, and PK (sc) Anetumab Ravtansine Bayer Mesothelin Mesothelioma (MPM) (BAY94-9343) Adenocarcinoma Solid tumors, with pemetrexed and cisplatin Advanced malignancies (Japan) Ovarian cancer, with doxorubicin Solid tumors with hepatic/renal impairment ECG & drug interaction (with itraconazole) BI-836845 BI IGF-1 Metastatic breast cancer CRPC + enzalutamide Solid tumors, Japanese patients EGFR mutant NSCLC BHQ880 Novartis DKK-1 MM (renal insufficiency) Smoldering MM Bimagrumab Novartis ActRIIB Hip fracture surgery (BYM338) Sarcopenia (dose-ranging) Sarcopenia (withdrawal extension study) BPS804 Mereo/Novartis Sclerostin Osteoporosis Hypophosphatasia (HPP) Osteogenesis Imperfecta © MorphoSys AG, Company Update - August 2016 11 Clinical Programs from Partnered Discovery Alliances (II) Program Partner Target Indication Phase 1 Phase 2 Phase 3 CNTO3157 Janssen/J&J Asthma Safety/Pharmacokintic CNTO6785 Janssen/J&J COPD Rheumatoid Arthritis LFG316 Novartis C5 Age-related geographic atrophy (tesidolumab) Geographic atrophy (combo with CLG561) Panuveitis Paroxysmal nocturnal hemoglobinuria Transplant Associated Microangiopathy (TAM) Kidney Transplantation LJM716 Novartis HER3 ESCC (combo with BYL719) (elgemtumab) HER2+ cancer (combo BYL719 & trastuzumab) HER2+ cancer, combo with trastuzumab Tarextumab Oncomed/GSK Notch 2 Small cell lung cancer (Pinnacle) (OMP-59R5) Solid tumors Utomilumab Pfizer 4-1BB JAVELIN Medley (PF-05082566) Solid tumors, NHL (+rituximab) Solid tumors, with PD-1i MK-3475 Advanced solid tumors, with mogamulizumab Solid tumors, with PF04518600 (OX-40) VAY736 Novartis BAFF-R Pemphigus vulgaris Primary Sjögren‘s syndrome Rheumatoid Arthritis BAY1093884 Bayer TFPI Bleeding disorders NOV-7 Novartis n.d. Eye disease NOV-8 Novartis n.d. Inflammation NOV-9 Novartis n.d. Diabetic eye disease NOV-10 Novartis n.d. Cancer NOV-11 Novartis n.d. Blood disorders Vantictumab Oncomed/Bayer Fzd 7 Metastatc breast cancer (OMP-18R5) Pancreatic cancer (combo) NSCL © MorphoSys AG, Company Update - August 2016 12 Guselkumab (CNTO1959) A Janssen Anti-Inflammatory Program Guselkumab A HuCAL antibody specific for IL-23, does not bind IL-12 IL-23 blockade inhibits production of multiple cytokines Being developed in psoriasis and psoriatic arthritis Current Status Six Phase 3 clinical trials ongoing First Phase 3 data expected in 2016 Anticipated filing in 2016 Clinical Data Highest levels of durable

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    24 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us